Direct-to-Biology (D2B) Drug Discovery Service By Pharmaron

Pharmaron poster promoting its Direct-to-Biology (D2B) approach to drug discovery with download option on a molecule-themed background.

Poster Authors:

Chris Wellaway¹, Sebastien Campos¹, Peng Chen², Pengxia Ding³, Qifeng Fu⁴, Chunyan Han³, Zhengqiao Huang⁴, Tong Jiang³, Christian Kuper¹, Lei Liu³, Manlin Liu³, Ruixue Liu⁴, Dan Moseley¹, Steven Sollis¹, Alison Stewart¹, Zixuan Tong¹, Yongcheng Wang², Joanne Wayne¹, Qiming Xiang⁴, Yaoshun Yang³, Wenjie Ye⁴, Rong Zhang³, Jie Zhao², Xin Zhao⁴, Ziwei Zhao²

¹ Pharmaron UK Ltd, Hoddesdon, UK

² Pharmaron, Xi’an, China

³ Pharmaron, Beijing, China

⁴ Pharmaron, Ningbo, China

Testing of Direct Reaction Mixture for Shorter DMTA Cycles through D2B Drug Discovery

This poster was presented at the ELRIG Drug Discovery 2025.

Direct-to-Biology (D2B) represents a transformative advance in drug discovery. By testing unpurified reaction mixtures directly in biological assays, D2B drug discovery accelerates the Design-Make-Test-Analyze (DMTA) cycle, reducing time, resource investments, and overall costs.

In this poster, we present Pharmaron’s D2B drug discovery platform for the discovery and optimization of Bifunctional Targeted Protein Degraders (TPDs).

Capabilities

Integrated Drug Discovery

Laboratory Chemistry

in vitro Biology

DMPK Services

Connect with a Scientific Expert

Complete the form below to access resource

Name(Required)

First Last

Company Name(Required)

Job Title(Required)

Country(Required)

State(Required)

Message

Email(Required)

This field is hidden when viewing the form

Lead Source(Required)

By completing and submitting this form, you acknowledge that you have read and understood our Privacy Policy, and you consent to the collection and processing of your personal data by Pharmaron for the purpose of responding to your inquiry. You also agree to be contacted by Pharmaron regarding relevant services and updates. You may withdraw your consent at any time.

Key Insights from our Direct-to-Biology Poster

Established D2B Drug Discovery Platform: We have successfully validated a D2B platform specifically designed for bifunctional targeted protein degraders, supported by a diverse toolbox of E3 ligase binders and linkers.
Validated Automation: The automated direct-to-biology chemistry workflow is validated in both 96-well and 384-well formats, achieving high conversion rates for reaction types like S_NAr and amide coupling.
High Data Agreement: Our results show excellent agreement between data from unpurified, micropurified, and purified compounds, confirming the reliability and robustness of our D2B drug discovery service.
Study Examples: We identify hits and reveal Structure-Activity Relationships (SAR) for BRD4 and AR-FL, demonstrating the practical impact of our platform.

Download the poster to gain deeper insight into our discovery-to-biology service, validation data, and example data.